.

Deeper Knowledge, Faster

  • Anticipate your formulary budget
  • Uncover prior art in expired and abandoned patents
  • Drug patents and clinical trials in dozens of countries

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Boehringer Ingelheim
Dow
US Army
Accenture
Colorcon
Citi
Cipla
Chubb
UBS

Generated: June 23, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 207233

« Back to Dashboard
NDA 207233 describes VIVLODEX, which is a drug marketed by Iroko Pharms Llc and is included in one NDA. It is available from one supplier. There are two patents protecting this drug and one Paragraph IV challenge. Additional details are available on the VIVLODEX profile page.

The generic ingredient in VIVLODEX is meloxicam. There are twenty-two drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the meloxicam profile page.

Summary for NDA: 207233

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Analgesics
Anti-inflammatory Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 207233

Suppliers and Packaging for NDA: 207233

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VIVLODEX
meloxicam
CAPSULE;ORAL 207233 NDA Iroko Pharmaceuticals, LLC 42211-205 42211-205-23 30 CAPSULE in 1 BOTTLE (42211-205-23)
VIVLODEX
meloxicam
CAPSULE;ORAL 207233 NDA Iroko Pharmaceuticals, LLC 42211-205 42211-205-29 90 CAPSULE in 1 BOTTLE (42211-205-29)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength5MG
Approval Date:Oct 22, 2015TE:RLD:Yes
Patent:9,526,734Patent Expiration:Mar 31, 2033Product Flag?YSubstance Flag?Delist Request?
Patent:9,649,318Patent Expiration:Mar 31, 2035Product Flag?YSubstance Flag?Delist Request?
Regulatory Exclusivity Expiration:Oct 22, 2018
Regulatory Exclusivity Use:NEW PRODUCT


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Citi
Daiichi Sankyo
Colorcon
Medtronic
Cerilliant
Teva
Federal Trade Commission
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot